首页> 美国卫生研究院文献>Journal of Drug Delivery >The Treatment of Breast Cancer Using Liposome Technology
【2h】

The Treatment of Breast Cancer Using Liposome Technology

机译:使用脂质体技术治疗乳腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Liposome-based chemotherapeutics used in the treatment of breast cancer can in principle enhance the therapeutic index of otherwise unencapsulated anticancer drugs. This is partially attributed to the fact that encapsulation of cytotoxic agents within liposomes allows for increased concentrations of the drug to be delivered to the tumor site. In addition, the presence of the phospholipid bilayer prevents the encapsulated active form of the drug from being broken down in the body prior to reaching tumor tissue and also serves to minimize exposure of the drug to healthy sensitive tissue. While clinically approved liposome-based chemotherapeutics such as Doxil have proven to be quite effective in the treatment of breast cancer, significant challenges remain involving poor drug transfer between the liposome and cancerous cells. In this review, we discuss the recent advancements made in the development of liposome-based chemotherapeutics with respect to improved drug transfer for use in breast cancer therapy.
机译:原则上,用于治疗乳腺癌的基于脂质体的化学治疗剂可以提高原本未封装的抗癌药物的治疗指数。这部分归因于以下事实:将细胞毒性剂包封在脂质体内允许将增加浓度的药物递送至肿瘤部位。另外,磷脂双层的存在防止了药物的包封的活性形式在到达肿瘤组织之前在体内分解,并且还用于使药物对健康敏感组织的暴露最小化。虽然已证明临床批准的基于脂质体的化学疗法(例如Doxil)在乳腺癌的治疗中非常有效,但仍然存在重大挑战,涉及脂质体与癌细胞之间不良的药物转移。在这篇综述中,我们讨论了基于脂质体的化学治疗药物在乳腺癌治疗中改善药物转移方面的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号